Changes in Postmenopausal Hormone Therapy Use Since 1988

Women's Health Issues

Volumn 17, Issue 6, 2007, Pages 338-341

  Kim, Jung Ki ^a   Alley, Dawn ^b   Hu, Peifeng ^c   Karlamangla, Arun ^c   Seeman, Teresa ^c   Crimmins, Eileen M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ESTROGEN;

ADULT; AGED; BREAST CANCER; DRUG USE; DRUG UTILIZATION; EDITORIAL; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HISTORY OF MEDICINE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; RISK BENEFIT ANALYSIS;

CLINICAL TRIALS AS TOPIC; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); EVIDENCE-BASED MEDICINE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MEDROXYPROGESTERONE; POSTMENOPAUSE; WOMEN'S HEALTH; WOMEN'S HEALTH SERVICES;

EID: 36248965171     PISSN: 10493867     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.whi.2007.05.001     Document Type: Editorial

References (25)

1. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Annals of Internal Medicine 117 (1992) 1039-1041
2. Brett K.M., and Madans J.H. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. American Journal of Epidemiology 145 (1997) 536-545
3. Bruist D.S., Newton K.M., Miglioretti D.L., Beverly K., Connelly M.T., Andrade S., et al. Hormone therapy prescribing patterns in the United States. Obstetrics and Gynecology 104 (2004) 1042-1050
4. Cushman M., Legault C., Barrett-Connor E., Stefanick M., Kessler C., Judd H., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100 (1999) 717-722
5. Ettinger B., Grady D., Tosteson A., Pressman A., and Macer J. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstetrics and Gynecology 102 (2003) 1225-1232
6. Ford E.S., Giles W.H., Mokdad A.H., and Myers G.L. Distribution and correlates of C-reactive protein concentrations among adult US women. Clinical Chemistry 50 (2004) 574-581
7. Haas J.S., Kaplan C.P., Gerstenberger E.P., and Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Annals of Internal Medicine 140 (2004) 184-188
8. Harris T.B., Ferrucci L., Tracy R.P., Corti M.C., Wacholder S., Ettinger W., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. American Journal of Medicine 106 (1999) 506-512
9. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. Journal of the American Medical Association 291 (2004) 47-53
10. Hing E., and Brett K.M. Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003. Obstetrics and Gynecology 108 (2006) 4-5
11. Kelly J.P., Kaufman D.W., Rosenberg L., Kelley K., Cooper S.G., and Mitchell A.A. Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiology and Drug Safety 14 (2005) 837-842
12. Kim J.K., Alley D., Seeman T., Karlamangla A., and Crimmins E. Recent changes in cardiovascular risk factors among women and men. Journal of Women's Health 15 (2006) 734-746
13. Koenig W., Sund M., Frohlich M., Fischer H., Lowel H., Doring A., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA Augsburg Cohort Study, 1984-1992. Circulation 99 (1999) 237-242
14. North American Menopause Society. Amended report from the NAMS advisory panel on postmenopausal hormone therapy. Menopause 10 (2003) 6-12
15. North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: September 2003 position statement of The North American Menopause Society. Menopause 10 (2003) 497-506
16. North American Menopause Society. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 11 (2004) 589-600
17. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., and Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association 286 (2001) 327-334
18. Pradhan A., Manson J., Rossouw J., Siscovick D., Mouton C., Rifai N., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease prospective analysis from the Women's Health Initiative Observational Study. Journal of the American Medical Association 288 (2002) 980-987
19. Ravdin P.M., Cronin K.A., Howlander N., Berg C.D., Chlebowski R.T., Feuer E.J., et al. The decrease in breast-cancer incidence in 2003 in the United States. New England Journal of Medicine 356 (2007) 1670-1674
20. Reuben D.B., Cheh A.I., Harris T.B., Ferrucci L., Rowe J.W., Tracy R.P., et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. Journal of the American Geriatrics Society 50 (2002) 638-644
21. Ridker P.M., Glynn R.J., and Hennekens C.H. CRP adds to the predictive value of total and HDL cholesterol in determining risk of first MI. Circulation 97 (1998) 2007-2011
22. Ridker P.M., Hennekens C.H., Rifai N., Buring J.E., and Manson J.E. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100 (1999) 713-716
23. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 288 (2002) 321-333
24. Schonberg M.A., Davis R.B., and Wee C.C. After the Women's Health Initiative: Decision making and trust of women taking hormone therapy. Women's Health Issues 15 (2005) 187-195
25. Smith S.C., Anderson J.L., Cannon R.O., Fadl Y., Koenig W., Libby P., et al. CDC/AHA Workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice report from the Clinical Practice Discussion Group. Circulation 110 (2004) e550-e553